Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Intern Med J ; 52(5): 790-799, 2022 05.
Artigo em Inglês | MEDLINE | ID: mdl-32687250

RESUMO

BACKGROUND: Guidelines recommend screening for strongyloidiasis prior to immunosuppression in those at epidemiological risk, as hyperinfection following immunosuppression is often fatal. The uptake of this recommendation is unknown and we aimed to explore this in our setting. AIMS: To determine the proportion of adult patients at epidemiological risk for strongyloidiasis who were screened prior to immunosuppression at the Royal Melbourne Hospital, and to explore the factors that influenced clinicians' decision to screen for strongyloidiasis prior to immunosuppression. METHODS: This study used a mixed-methods approach. First, a 12-month (1 January 2018 to 1 January 2019) retrospective observational study was used to quantify the proportion of those at epidemiological risk who were screened prior to immunosuppression, while also identifying variables that were positively or negatively associated with screening. Second, clinicians from relevant specialties were recruited for focus group sessions to explore factors that influenced their decision to screen according to an interpretivist framework. RESULTS: A total of 230 newly immunosuppressed patients at epidemiological risk of strongyloidiasis were identified, of whom 87 (37.8%) were screened prior to immunosuppression. In multivariate analysis, older patients, outpatients and people from non-English-speaking backgrounds were significantly less likely to be screened. In focus groups, several barriers and enablers to screening were identified. Notably, clinicians reported that a major barrier was the cognitive load required to clinically reason about this uncommon disease, in addition to other priorities. CONCLUSIONS: We identified many missed opportunities to screen patients at risk of hyperinfection, particularly those most vulnerable. To improve screening, this study highlights the importance of reducing cognitive load by using decision-support tools, which may facilitate screening in vulnerable patients and in time-constrained settings.


Assuntos
Síndromes de Imunodeficiência , Strongyloides stercoralis , Estrongiloidíase , Adulto , Animais , Humanos , Hospedeiro Imunocomprometido , Terapia de Imunossupressão/efeitos adversos , Programas de Rastreamento , Estrongiloidíase/diagnóstico , Estrongiloidíase/epidemiologia
2.
Am J Trop Med Hyg ; 103(6): 2318-2322, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-32959773

RESUMO

Neurocysticercosis (NCC) is a disease caused by infection of the central nervous system with the larval stage of the tapeworm Taenia solium. This disease is endemic in many parts of the world, including Africa, Asia, and Latin America, where animal husbandry practices are common such that pigs reared for human consumption ingest feces from humans infected with T. solium. Neurocysticercosis is rarely acquired in economically affluent regions, including North America, Central Europe, Japan, and Australasia, and in countries where pork consumption is discouraged by religious or social practices. In these countries, NCC is usually diagnosed in immigrants or returning travelers who have spent time in endemic regions. Here, we report a case of NCC in a 25-year-old woman presenting with worsening visual symptoms in association with headache, diagnosed previously as a migraine with visual aura. This person had always lived in Australia and had never traveled overseas to a country endemic for T. solium. The unusual features of the clinical presentation and epidemiology are highlighted to raise physicians' awareness that attention needs to be paid to the risk of autochthonous infection occurring in non-endemic countries.


Assuntos
Edema Encefálico/diagnóstico por imagem , Neurocisticercose/diagnóstico por imagem , Lobo Occipital/diagnóstico por imagem , Adulto , Animais , Austrália , Edema Encefálico/terapia , DNA de Helmintos/análise , Transmissão de Doença Infecciosa , Feminino , Humanos , Imageamento por Ressonância Magnética , Neurocisticercose/patologia , Neurocisticercose/terapia , Neurocisticercose/transmissão , Lobo Occipital/patologia , Lobo Occipital/cirurgia , Reação em Cadeia da Polimerase , Taenia solium/genética
3.
J Clin Endocrinol Metab ; 104(6): 2229-2238, 2019 06 01.
Artigo em Inglês | MEDLINE | ID: mdl-30602021

RESUMO

CONTEXT: Androgen deprivation therapy (ADT) for prostate cancer (PCa) leads to a selective loss of leg muscle function during walking. Rodent models of ADT have demonstrated that the levator ani is exquisitely androgen sensitive. OBJECTIVE: To determine whether the high androgen responsiveness of the levator ani muscle documented in rodents is evolutionarily conserved and ADT is associated with a selective loss in leg muscle volume. DESIGN: Prospective longitudinal case-control study. SETTING: Tertiary referral hospital. PARTICIPANTS: Thirty-four men newly beginning ADT and 29 age-matched controls with PCa. MAIN OUTCOME MEASURES: The muscle volumes in liters of the levator ani and primary muscles involved in walking (iliopsoas, quadriceps, gluteus maximus, gluteus medius, calf). RESULTS: Compared with controls, during a 12-month period, men receiving ADT experienced a mean reduction in total testosterone from 14.1 to 0.4 nmol/L and demonstrated greater decreases in levator ani [mean adjusted difference (MAD), -0.005 L; 95% CI, -0.007 to -0.002; P = 0.002; -16% of initial median value], gluteus maximus (MAD, -0.032 L; 95% CI, -0.063 to -0.002; P = 0.017; -5% of initial median value), iliopsoas (MAD, -0.005 L; 95% CI, -0.001 to 0.000; P = 0.013; -5% of initial median value), and quadriceps (MAD, -0.050 L; 95% CI, -0.088 to -0.012; P = 0.031; -3% of initial median value). No substantial differences were observed in the gluteus medius and calf muscles. CONCLUSIONS: The androgen responsiveness of the levator ani appears to be evolutionarily conserved in humans. ADT selectively decreases the volume of muscles that support body weight. Interventional strategies to reduce ADT-related sarcopenia and sexual dysfunction should assess whether targeting these muscle groups, including the pelvic floor, will improve clinical outcomes.


Assuntos
Antagonistas de Androgênios/efeitos adversos , Músculo Esquelético/efeitos dos fármacos , Idoso , Composição Corporal/efeitos dos fármacos , Humanos , Perna (Membro) , Masculino , Pessoa de Meia-Idade , Músculo Esquelético/patologia , Estudos Prospectivos , Sarcopenia/induzido quimicamente , Disfunções Sexuais Fisiológicas/induzido quimicamente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA